Altimmune starts PERFORMA, a registrational Phase 3 of pemvidutide in MASH

Altimmune said on August 3, 2026 that it has started PERFORMA, a global, randomized, double-blind, placebo-controlled Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH. The trial is registrational, meaning it is designed to support an eventual application for FDA approval. It will measure whether the drug improves liver fibrosis, resolves MASH, and improves clinical outcomes.^[1]

Pemvidutide is a dual agonist that acts on both the GLP-1 receptor and the glucagon receptor. The glucagon component is meant to drive fat loss directly in the liver, which is the basis for Altimmune's argument that the drug could help with both obesity and liver disease. In an earlier obesity study, pemvidutide produced 15.6% weight loss at 48 weeks.^[1]

PERFORMA follows 48-week data from the IMPACT Phase 2b trial in MASH, presented at the European Association for the Study of the Liver meeting earlier in 2026. That data was described as positive, though the specific fibrosis and resolution rates from IMPACT are not detailed in the available sources.^[1]

Pemvidutide has also shown effects outside metabolic disease. A separate Phase 2 trial called RECLAIM, in alcohol use disorder, met its primary endpoint on July 28, 2026, with a 9.1% weight loss difference versus placebo and other registrational secondary endpoints also met, according to industry tracking.^[1] Altimmune is a small company by pharmaceutical industry standards, with a market capitalization of roughly $440 million to $590 million as of July 2026 and about $535 million in cash as of April 30, 2026, which included a $225 million raise that same month.^[1] Second-quarter financial results were expected on August 12, 2026.^[1]

Why it matters for patients

MASH is a form of fatty liver disease that can progress to cirrhosis and liver failure. Right now there are very few approved drug treatments for it, so a large Phase 3 trial testing a GLP-1/glucagon combination is relevant to anyone managing fatty liver disease alongside excess weight. Industry analysis frames MASH as a nearer-term regulatory path for pemvidutide than obesity, since the obesity market for GLP-1 and dual-agonist drugs is already crowded with approved options such as semaglutide (Wegovy) and tirzepatide (Zepbound), and later-stage candidates including retatrutide and CagriSema.^[1]

For patients currently taking or considering GLP-1 medicines for weight loss, pemvidutide is not an approved option and is not close to one. It remains in Phase 3 testing for MASH and Phase 2 for obesity. The company's pitch — that its glucagon-driven mechanism preserves muscle while burning fat and also benefits the liver — has not yet been confirmed in late-stage trials, and Altimmune itself is a small, speculative company operating in a crowded field, according to the same industry tracking source.^[1]

People with both obesity and liver disease may eventually have more options if PERFORMA succeeds, but that outcome is years away and unproven.

What happens next

Altimmune reported second-quarter 2026 financial results on August 12, 2026, which would typically include updated enrollment or timeline detail for PERFORMA, though those specifics are not included in the sources reviewed here.^[1] No date for PERFORMA's primary completion or topline readout is given in the available material. Investors and patients watching this program will need enrollment numbers, a target completion date, and eventually the fibrosis and MASH-resolution results themselves before any conclusions about effectiveness can be drawn.